To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Primary Objectives:
Phase 2 Simon 2-Stage Study (Arm 1 Monotherapy)
Phase 1b (Arm 2 Combination Therapy)
Phase 2 Exploratory Study (Arm 2 Combination Therapy)
Secondary Objectives:
Phase 1b Study (Arm 2 Combination Therapy)
Participant must have radiographic evidence of disease progression based on RECIST criteria following the most recent line of treatment. Biochemical recurrence (eg, CA-125 in ovarian carcinoma) only is not considered as disease progression.
Newly obtained is defined as a specimen obtained up to 6 weeks prior to initiation of treatment on Day 1 if no intercurrent systemic therapy in the interval.
Tumor Specific Inclusion Criteria
For Ovarian Carcinoma:
Platinum sensitive disease, defined as disease which progress after 6 or more months after the completion of platinum-based therapy and primary platinum refractory disease, defined as progression while on the upfront platinum-based therapy, is not eligible.
For Endometrial Carcinoma
For Urothelial Carcinoma
Tumor Specific Exclusion Criteria
For Endometrial Adenocarcinoma:
For Urothelial Carcinoma: